Are statins created equal? Evidence from randomized trials of pravastatin, simvastatin, and atorvastatin for cardiovascular disease prevention.
about
Enteric microbiome metabolites correlate with response to simvastatin treatmentSimvastatin is associated with a reduced incidence of dementia and Parkinson's diseaseCarriage of the V279F null allele within the gene encoding Lp-PLA₂ is protective from coronary artery disease in South Korean malesStatin induced myopathy presenting as mechanical musculoskeletal pain observed in two chiropractic patients.Indirect comparisons: a review of reporting and methodological qualityStatins, antihypertensive treatment, and blood pressure control in clinic and over 24 hours: evidence from PHYLLIS randomised double blind trial.Does combination therapy with statins and fibrates prevent cardiovascular disease in diabetic patients with atherogenic mixed dyslipidemia?Lipidomic analysis of variation in response to simvastatin in the Cholesterol and Pharmacogenetics Study.Efficacy and safety of statin treatment for cardiovascular disease: a network meta-analysis of 170,255 patients from 76 randomized trials.Statins, the renin-angiotensin-aldosterone system and hypertension - a tale of another beneficial effect of statins.A clinical evaluation of statin pleiotropy: statins selectively and dose-dependently reduce vascular inflammationChronic pravastatin but not atorvastatin treatment impairs cognitive function in two rodent models of learning and memorySitagliptin/Simvastatin: a first combination tablet to treat type 2 diabetes and hypercholesterolemia--a review of its characteristicsStatins in elderly patients with acute coronary syndrome: an analysis of dose and class effects in typical practice.Challenges to evidence-based prescribing in clinical practice.Statins in lymphangioleiomyomatosis. Simvastatin and atorvastatin induce differential effects on tuberous sclerosis complex 2-null cell growth and signaling.Highly stereoselective hydrogenations--as key-steps in the total synthesis of statins.A systematic review and meta-analysis on the therapeutic equivalence of statins.Modern approach to metabolic rehabilitation of cancer patients: biguanides (phenformin and metformin) and beyond.Intensive statin therapy compared with moderate dosing for prevention of cardiovascular events: a meta-analysis of >40 000 patients.Fenofibrate plus simvastatin (fixed-dose combination) for the treatment of dyslipidaemia.Targeting tumor cell metabolism with statins.The ezetimibe controversy - can this be resolved by comparing the clinical trials with simvastatin and ezetimibe alone and together?Lipids and cardiovascular disease: where does dietary intervention sit alongside statin therapy?Pharmacological management of diabetic dyslipidemia.Gut Microbiota Modulation Attenuated the Hypolipidemic Effect of Simvastatin in High-Fat/Cholesterol-Diet Fed Mice.Secondary prevention of major cerebrovascular events with seven different statins: a multi-treatment meta-analysis.Impact of chronic anticholesterol therapy on development of microvascular rarefaction in the metabolic syndrome.Characterization of human erythrocytes as potential carrier for pravastatin: an in vitro study.Mechanism of beneficial effects of physical activity on atherosclerosis and coronary heart disease.Would a national pharmaceutical strategy be bad for the cardiovascular health of Canadians?Pharmacokinetics and bioequivalence study of two tablet formulations of lovastatin in healthy volunteers.Pretreatment with high-dose statin, but not low-dose statin, ezetimibe, or the combination of low-dose statin and ezetimibe, limits infarct size in the rat.Atorvastatin attenuates mitochondrial toxin-induced striatal degeneration, with decreasing iNOS/c-Jun levels and activating ERK/Akt pathways.Using lower cost statins improves outcomes for normal cholesterol non-diabetic patients.Statins impair survival of primary human mesenchymal progenitor cells via mevalonate depletion, NF-κB signaling, and Bnip3.
P2860
Q21135141-0774E0AA-8829-4BC9-849E-4DAEFE513155Q24673755-EE17AE79-CCF5-405E-AACB-88C8C9809A76Q28741376-277F7F76-A8BD-4C83-AD8B-B2463869B239Q33692765-C79A0C05-2AFC-4B27-96F9-6DFF3CC8AFD6Q33750311-025215EC-7CDD-47E3-9EB8-D0E9B6ED8BFCQ33754137-3830669A-ED09-4589-8B6A-10BFE853B580Q33776187-CB87D329-395E-4DE7-884C-7008B65CF1DDQ33824051-6C123574-FB51-43F8-9FB3-3FE824274E00Q34142678-8BB29BC4-EE44-4A36-A47E-729FC895AFC0Q34429685-63ABC69B-1574-41AD-91F7-881F8EFDF5CAQ34562390-577B3C56-AA23-4C75-BC9C-2616FCB8CBFAQ34990621-D57D1D06-901A-4490-9DDD-D3B31A376009Q35100483-098C467F-BDFD-4A09-874C-B18DF28081AFQ36014026-2E963EC5-19DD-47AD-A263-11D975F23D18Q37138863-4530FF78-D67A-4D98-8387-EBC8078363DDQ37596461-5D9D9001-5457-4EF0-9E13-C6D1A379F27FQ37629758-CAAB6D02-B520-4DF2-969F-A5573A4793FBQ37747986-C2ABCF37-9A57-4E85-A85B-7639701BE757Q37783621-0261858B-A63A-4A06-80AD-99062BBAD657Q37850870-5EFFFE59-F8CB-448F-A73D-B6EDD99E3659Q37898699-DB3268D3-80C2-41ED-B499-87363F9028BDQ37981833-7E7422A7-2402-483C-944D-EAF5E55A2BA4Q38020942-6EEBC3FA-9980-4C56-9EF4-56F1D28456B6Q38816273-88557AAA-2C4C-4B28-9FA1-FB21A1FF110CQ39015072-15533BCE-DE5C-4ED5-BD23-7B03075EE532Q40257529-47940E00-968F-49F4-950A-05F78E29289BQ41633477-95CF295C-45AA-4000-9B39-7ABDBC835602Q42133595-44304419-4E1F-4EFE-A5BB-DE3DBD8F1D73Q42705033-0AE09F15-B072-4201-813C-592E49DD6CA9Q42817864-569A805C-83A4-4176-8303-814F4CA2CEC5Q43167477-1EBD749E-ED38-4AB7-A3C8-63734358A2BBQ46739223-5E21B626-29EF-4C6D-9FFD-271E0F20C4CFQ46743802-6F537B98-A75D-48EC-ADC6-AA30B0BC8222Q46919908-E2BCC722-25DE-440E-A33F-E1AA99AF4F62Q48145028-AC301E0A-D6B3-47B1-8595-D561E4F89DAEQ53651473-1625477B-F924-4AEE-AC55-130DB30EB78C
P2860
Are statins created equal? Evidence from randomized trials of pravastatin, simvastatin, and atorvastatin for cardiovascular disease prevention.
description
2006 nî lūn-bûn
@nan
2006 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Are statins created equal? Evi ...... iovascular disease prevention.
@ast
Are statins created equal? Evi ...... iovascular disease prevention.
@en
Are statins created equal? Evi ...... iovascular disease prevention.
@nl
type
label
Are statins created equal? Evi ...... iovascular disease prevention.
@ast
Are statins created equal? Evi ...... iovascular disease prevention.
@en
Are statins created equal? Evi ...... iovascular disease prevention.
@nl
prefLabel
Are statins created equal? Evi ...... iovascular disease prevention.
@ast
Are statins created equal? Evi ...... iovascular disease prevention.
@en
Are statins created equal? Evi ...... iovascular disease prevention.
@nl
P1476
Are statins created equal? Evi ...... iovascular disease prevention.
@en
P2093
Elham Rahme
Zheng Zhou
P304
P356
10.1016/J.AHJ.2005.04.003
P407
P577
2006-02-01T00:00:00Z